Skip to main content

28.11.2016 | Original Article | Ausgabe 3/2018

Journal of Nuclear Cardiology 3/2018

Safety of regadenoson stress testing in patients with pulmonary hypertension

Journal of Nuclear Cardiology > Ausgabe 3/2018
MD Victor M. Moles, MD Thomas Cascino, MD Ashraf Saleh, MD Krasimira Mikhova, MD John J. Lazarus, MD Michael Ghannam, MD Hong J. Yun, MD Matthew Konerman, MD, PhD Richard L. Weinberg, PhD Edward P. Ficaro, MD James R. Corbett, MD Vallerie V. McLaughlin, MD, PhD Venkatesh L. Murthy
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1007/​s12350-016-0734-6) contains supplementary material, which is available to authorized users.
The authors of this article have provided a PowerPoint file, available for download at SpringerLink, which summarises the contents of the paper and is free for re-use at meetings and presentations. Search for the article DOI on SpringerLink.​com.


No grants, contracts, or other forms of financial support were used in this study.



We sought to determine the safety of regadenoson stress testing in patients with PH.


PH is increasingly recognized at more advanced ages. As many as one-third of patients with PH have coronary artery disease. Because of their physical limitations, patients with PH are unable to adequately exercise. Regadenoson can potentially have an adverse impact due to their tenuous hemodynamics. Current guidelines suggest performing a coronary angiography in patients with PH who have angina or multiple coronary risk factors.


We identified 67 consecutive patients with confirmed PH by catheterization (mean PA > 25 mmHg not due to left heart disease) who underwent MPI with regadenoson stress. Medical records were reviewed to determine hemodynamic and ECG response to regadenoson.


No serious events occurred. Common side effects related to regadenoson were observed, dyspnea being the most common (70.6%). No syncope occurred. Heart rate increased from 74.6 ± 14 to 96.3 ± 18.3 bpm, systolic blood pressure increased from 129.8 ± 20.9 to 131.8 ± 31 mmHg, and diastolic blood pressure decreased from 77.1 ± 11.4 to 72.9 ± 15.3 mmHg. There was no ventricular tachycardia, ventricular fibrillation, or second- or third-degree atrioventricular block.


Regadenoson stress MPI appears to be well tolerated and safe in patients with PH.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

Weitere Produktempfehlungen anzeigen
Supplementary material 1 (PPTX 381 kb)
Über diesen Artikel

Weitere Artikel der Ausgabe 3/2018

Journal of Nuclear Cardiology 3/2018Zur Ausgabe
  1. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.

  2. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.

Neu im Fachgebiet Kardiologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Kardiologie und bleiben Sie gut informiert – ganz bequem per eMail.